

Occurrence and Elimination of Pharmaceuticals During Conventional Wastewater Treatment

Aleksandra Jelić, Meritxell Gros, Mira Petrović, Antoni Ginebreda,
and Damià Barceló

Abstract Pharmaceuticals have an important role in the treatment and prevention of disease in both humans and animals. Since they are designed either to be highly active or interact with receptors in humans and animals or to be toxic for many infectious organisms, they may also have unintended effects on animals and microorganisms in the environment. Therefore, the occurrence of pharmaceutical compounds in the environment and their potential effects on human and environmental health has become an active subject matter of actual research.

There are several possible sources and routes for pharmaceuticals to reach the environment, but wastewater treatment plants have been identified as the main point of their collection and subsequent release into the environment, via both effluent wastewater and sludge. Conventional systems that use an activated sludge process are still widely employed for wastewater treatment, mostly because they produce effluents that meet required quality standards (suitable for disposal or recycling purposes), at reasonable operating and maintenance costs. However,

A. Jelić (✉) • A. Ginebreda

Institute of Environmental Assessment and Water Research (IDAEA-CSIC), C/Jordi Girona,
18-26, 08034 Barcelona, Spain
e-mail: aljqam@cid.csic.es

M. Gros

Catalan Institute for Water Research (ICRA), c/Emili Grahit 101, 17003 Girona, Spain

M. Petrović

Catalan Institute for Water Research (ICRA), c/Emili Grahit 101, 17003 Girona, Spain

Catalan Institution for Research and Advanced Studies (ICREA), Passeig Lluís Companys 23,
80010 Barcelona, Spain

D. Barceló

Institute of Environmental Assessment and Water Research (IDAEA-CSIC), C/Jordi Girona,
18-26, 08034 Barcelona, Spain

Catalan Institute for Water Research (ICRA), c/Emili Grahit 101, 17003 Girona, Spain

King Saud University (KSU), P.O. Box 2455, 11451 Riyadh, Saudi Arabia

this type of treatment has been shown to have limited capability of removing pharmaceuticals from wastewater. The following chapter reviews the literature data on the occurrence of these microcontaminants in wastewater influent, effluent, and sludge, and on their removal during conventional wastewater treatment.

Keywords Pharmaceuticals • Removal • Sludge • Wastewater

Contents

1	Introduction	2
2	Activated Sludge Process for Treatment of Wastewater	4
3	Occurrence of Pharmaceuticals During Conventional Wastewater Treatment	4
3.1	Occurrence of Pharmaceuticals in Wastewater Influent and Effluent	4
3.2	Occurrence of Pharmaceuticals in Sewage Sludge	9
4	Removal of Pharmaceuticals During Conventional Wastewater Treatment	12
5	Conclusion	16
	References	17

Abbreviations

HRT	Hydraulic retention time
NSAIDs	Nonsteroidal anti-inflammatory drugs
SRT	Solid retention time
WWTP	Wastewater treatment plant

1 Introduction

Pharmaceuticals are a large and diverse group of compounds designed to prevent, cure, and treat disease, and improve health. Hundreds of tons of pharmaceuticals are dispensed and consumed annually worldwide. The usage and consumption are increasing consistently due to the discoveries of new drugs, the expanding population, and the inverting age structure in the general population, as well as due to expiration of patents with resulting availability of less expensive generics [1]. After intake, these pharmaceutically active compounds undergo metabolic processes in organisms. Significant fractions of the parent compound are excreted in unmetabolized form or as metabolites (active or inactive) into raw sewage and wastewater treatment systems. Municipal sewage treatment plant effluents are discharged to water bodies or reused for irrigation, and biosolids produced are reused in agriculture as soil amendment or disposed to landfill. Thus body metabolism and excretion followed by wastewater treatment are considered to be the primary pathway of pharmaceuticals to the environment. Disposal of drug leftovers to sewage and trash is another source of entry, but its relative significance is unknown with respect to the overall levels of pharmaceuticals in the environment [2].

Continual improvements in analytical equipment and methodologies enable the determination of pharmaceuticals at lower concentration levels in different environmental matrices. Pharmaceuticals and their metabolites in surface water and aquatic sediment were subject of numerous studies concerning pharmaceuticals in the environment [3–5]. Several studies investigated the occurrence and distribution of pharmaceuticals in soil irrigated with reclaimed water [6–8] and soil that received biosolids from urban sewage treatment plants [9, 10]. These studies indicated that the applied wastewater treatments are not efficient enough to remove these micropollutants from wastewater and sludge, and as a result they find their way into the environment (Fig. 1). Once they enter the environment, pharmaceutically active compounds can produce subtle effects on aquatic and terrestrial organisms, especially on the former since they are exposed to long-term continuous influx of wastewater effluents. Several studies investigated and reported on it [11–13]. No evidence exists linking the presence of pharmaceuticals in the environment to human health risks; still complex mixtures may have long-term unseen effects, especially on tissues other than those on which the pharmaceuticals were designed to act.

Therefore, the occurrence of pharmaceutical compounds in the environment and their potential effects on human and environmental health, as well as the extent to which they can be eliminated during wastewater treatment, have become active subject matter of actual research. Since the concern about the discharge of pharmaceuticals (and other emerging contaminants, as well) into wastewater is relatively recent, it is not strange that they are not yet covered by the currently existing regulation.




Fig. 1 Routes of release of pharmaceuticals for human use to the environment with a schematic diagram of a conventional WWTP

2 Activated Sludge Process for Treatment of Wastewater

Wastewater treatment systems that use activated sludge processes have been employed extensively throughout the world, mostly because they produce effluents that meet required quality standards (suitable for disposal or recycling purposes), at reasonable operating and maintenance costs. Figure 1 shows a schematic diagram of a conventional wastewater treatment. All design processes include preliminary treatment consisting of bar screen, grit chamber, and oil and grease removal unit [14], typically followed by primary gravity settling tank, in all but some of the smaller treatment facilities. The primary-treated wastewater enters into a biological treatment process—usually an aerobic suspended growth process—where mixed liquor (i.e., microorganisms responsible for the treatment, along with biodegradable and nonbiodegradable suspended, colloidal, and soluble organic and inorganic matter) is maintained in liquid suspension by appropriate mixing methods. During the aeration period, adsorption, flocculation, and oxidation of organic matter occur. After enough time for appropriate biochemical reactions, mixed liquor is transferred to a settling reactor (clarifier) to allow gravity separation of the suspended solids (in form of floc particles) from the treated wastewater. Settled solids are then returned to the biological reactor (i.e., return activated sludge) to maintain a concentrated biomass for wastewater treatment. Microorganisms are continuously synthesized in the process; thus some of suspended solids must be wasted from the system in order to maintain a selected biomass concentration in the system. Wasting is performed by diverting a portion of the solids from the biological reactor to solid-handling processes. The most common practice is to waste sludge from the return sludge line because return activated sludge is more concentrated and requires smaller waste sludge pumps. The waste sludge can be discharged to the primary sedimentation tanks for co-thickening, to thickening tanks, or to other sludge-thickening facilities, in order to increase the solid content of sludge by removing a portion of the liquid fraction. Through the subsequent processes such as digestion, dewatering, drying, and combustion, the water and organic content is considerably reduced, and the processed solids are suitable for reuse or final disposal. To achieve better effluent water quality, further treatment steps - tertiary treatment - can be added to the above outlined general process, e.g. activated carbon adsorption, additional nutrient removal etc.

3 Occurrence of Pharmaceuticals During Conventional Wastewater Treatment

3.1 *Occurrence of Pharmaceuticals in Wastewater Influent and Effluent*

More than 10,000 prescription and over-the-counter pharmaceuticals are registered and approved for usage today, with around 1,300 unique active ingredients (Orange

book, FDA). This is a versatile group of compounds that differ in the mode of action, chemical structure, physicochemical properties, and metabolism. They are typically classified using the Anatomical Therapeutic Chemical Classification System (ATC system) according to their therapeutic application and chemical structure. Because of the volume of prescription, the toxicity, and the evidence for presence in the environment, nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, beta-blockers, antiepileptics, blood lipid-lowering agents, antidepressants, hormones, and antihistamines were the most studied pharmaceutical groups [15].

Even though a number of research publications have been focused on the occurrence, fate, and effects of pharmaceuticals in the environment, we have data on the occurrence of only 10% of the registered active compounds, and very little information on their effects in the environment. There is even less information regarding the occurrence and fate of the transformation/degradation products (active or not) of pharmaceuticals. Both the qualitative and the quantitative analysis of pharmaceuticals in the environmental matrices are definitely a starting point for the establishment of new regulations for the environmental risk assessment of pharmaceutical products.

The pharmaceuticals find their way to the environment primarily via the discharge of raw and treated sewage from residential users or medical facilities. Through the excretion via urine and feces, extensively metabolized drugs are released into the environment. But the topically applied pharmaceuticals (when washed off) along with the expired and unused ones (when disposed directly to trash or sewage) pose a direct risk to the environment because they enter sewage in their unmetabolized and powerful form [2]. Even though the production of drugs is governed by rigorous regulations, pharmaceutically active substances are frequently released with the waste from drug manufacturing plants [16–18].

The occurrence of the pharmaceutical compounds in wastewater treatment plants has been investigated in several countries around the world (Austria, Canada, England, Germany, Greece, Spain, Switzerland, USA, etc). More than 150 pharmaceuticals belonging to different therapeutic groups have been detected in concentration ranging up to the $\mu\text{g/L}$ level in sewage water. Their environmental occurrence naturally depends on the rate of production, the dosage and frequency of administration and usage, the metabolism and environmental persistence, as well as the removal efficiency of wastewater treatment plants (WWTPs). Figures 2 and 3 show the occurrence of the selected, most investigated pharmaceuticals in wastewater influent and effluent, as found in the literature.

NSAIDs are the most used class of drugs for the treatment of acute pain and inflammation. They are administered both orally and topically and available as prescription and over-the-counter (nonprescription) drugs. High consumption and way of administration of NSAIDs result in elevated concentration reported in the effluent from WWTPs. Among the most studied NSAIDs during wastewater treatments are ibuprofen, diclofenac, naproxen, ketoprofen, and mefenamic acid [19]. The compounds usually detected in the highest concentrations in the influent of WWTPs are ibuprofen, naproxen, and ketoprofen (in range of some $\mu\text{g/L}$)




Fig. 2 Concentrations of the pharmaceuticals in wastewater influent (25th, median, and 75th percentile, for the values found in the literature)




Fig. 3 Concentrations of the pharmaceuticals in wastewater effluent (25th, median, and 75th percentile, for the values found in the literature)

[20–22]. Even though the concentrations of these compounds are markedly lowered at the effluent, they are far from negligible. Heberer et al. [23] identified diclofenac as one of the most important pharmaceuticals in the water cycle, with low $\mu\text{g/L}$ concentrations in both raw and treated wastewater (3.0 and 2.5 $\mu\text{g/L}$ at the influent and effluent, respectively).

Beta-blockers are another very important class of prescription drugs. They are very effective in treating cardiovascular diseases. As NSAIDs, beta-blockers are not highly persistent, but they are present in the environment due to their high volume of use. Due to same mode of action of beta-blockers, it has been found that the mixture of beta-blockers showed concentration addition indicating a mutual specific nontarget effect on algae [24]. These compounds are generally found in aqueous phase because of their low sorption affinity and elevated biodegradability [25]. Atenolol, metoprolol, and propranolol have been frequently identified in wastewaters, where atenolol was detected in the highest concentrations, in some cases ranging up to 1 µg/L [26–28]. As a result of the incomplete removal during conventional wastewater treatment, these compounds were also found in surface waters in the ng/L to low mg/L range ([29, 30]; Ternes et al. 1998; [27]).

Lipid-lowering drugs, with statins and fibrates particularly, are used in the treatment and prevention of cardiovascular disease. In the last decade, statins became the drug of choice to lower cholesterol levels and their usage is increasing. According to the National Center for Health Statistics of USA [32], from 1988–1994 to 2003–2006, the use of statin drugs by adults aged 45 years and over increased almost tenfold, from 2 to 22%. Among lipid-lowering drugs and pharmaceuticals, in general, clofibric acid is one of the most frequently detected in the environment and one of the most persistent drugs with an estimated persistence in the environment of 21 years [15]. It has been detected in the ng/L range concentrations in influent, without big difference in the concentrations at the effluent. Many analogues of clofibrate, such as gemfibrozil, bezafibrate, and fenofibrate, were detected in the samples of sewage plants in concentrations up to low µg/L at the influent [20, 27, 33]. Among statins, atorvastatin, mevastatine, and prevastatine were detected in various environmental matrices including raw and treated wastewater as well as surface water near the points of discharge [20, 30, 34–36].

Antibiotics are destined to treat diseases and infection caused by bacteria. They are among the most frequently prescribed drugs for humans and animals in modern medicine. Beta-lactams, macrolides, sulfonamides, fluoroquinolones, and tetracyclines are the most important antibiotic groups used in both human and veterinary medicine. High global consumption of up to 200,000 tons per year [37] and high percentage of antibiotics that may be excreted without undergoing metabolism (up to 90%) result in their widespread presence in the environment [38]. Unmetabolized pharmaceutically active forms of antibiotics concentrated in raw sludge may promote the development of bacterial resistance. Bacteria in raw sludge are more resistant than bacteria elsewhere [39]. Many active antibiotic substances were found in raw sewage matrices, including both aqueous and solid phase. Beta-lactams are among the most prescribed antibiotics. Despite their high usage, they readily undergo hydrolysis, and thus have been detected in very low concentrations in treated wastewater, or not at all detected [40]. Sulfonamides, fluoroquinolone, and macrolide antibiotics show the highest persistence and are frequently detected in wastewater and surface waters [38]. Sulfamethoxazole is one of the most detected sulfonamides [41–45] that was reported with various concentrations and up to ca. 8µg/L (in raw influent in China) [46]. Sulfamethoxazole

is often administrated in combination with trimethoprim, and commonly analyzed together [47]. Trimethoprim exhibits high persistence with little removal being effected by WWTPs, and thus is ubiquitously detected in ranges from very low ng/L to 1 µg/L in wastewater influent and effluent [41, 48]. Fluoroquinolone antibiotics ciprofloxacin and norfloxacin have been frequently detected in various streams in low µg/L [22, 41, 49, 50]. Even though it is greatly reduced during treatment, ciprofloxacin was found to be present in effluent wastewater at average concentration from 0.1 to 0.6 µg/L [48, 51, 52]. The class of tetracyclines, widely used broad-spectrum antibiotics, with chlortetracycline, oxytetracycline, and tetracycline as mostly used, was detected in raw and treated sewage in many studies in the ng/L [53] to µg/L concentrations [54]. Tetracyclines and fluoroquinolones form stable complexes with particulates and metal cations, showing the capacity to be more abundant in the sewage sludge [55, 56]. Some of the most prescribed antibiotics—macrolides clarithromycin, azithromycin, roxithromycin, and dehydro-erythromycin—were found in various environmental matrices in a variety of concentrations from very low ng/L to few µg/L [57–59]. High effluent concentrations were reported for dehydro-erythromycin, i.e., up to 2.5 µg/L [51, 54, 60]. In the final US EPA report CCL-3 from September 2009, erythromycin was one of three pharmaceuticals included as priority drinking water contaminant, based on health effects and occurrence in environmental waters [61].

According to the National Center for Health Statistics of USA [32], the usage of *antidiabetic drugs* by adults aged 45 years and over increased about 50%, from 7% in 1988–1994 to 11% in 2003–2006, as a consequence of an increase in the detection of antidiabetics in the environment over time. Still, only few data are reported on the occurrence and fate of antidiabetics. Glyburide (also glibenclamide) was found to be ubiquitous in both aqueous and solid phase of sewage treatment [20, 30, 62].

Histamine H₂-receptor antagonists are used in the treatment of peptic ulcer and gastro-esophageal reflux disease. Certain preparations of these drugs are available OTC in various countries. Among H₂-receptor antagonists, cimetidine and ranitidine have been frequently detected in wastewater and sludge. As for all the other pharmaceuticals, the reported concentration varies from very low ng/L to a few µg/L [20, 21, 63].

While antiepileptic carbamazepine is one of the most studied and detected pharmaceuticals in the environment, there is not much information on the occurrence and fate of other of psychoactive drugs in WWTPs. Carbamazepine is one of the most widely prescribed and very important drug for the treatment of epilepsy, trigeminal neuralgia, and some psychiatric diseases (e.g., bipolar affective disorders [64, 65]). In humans, following oral administration, it is metabolized to pharmacologically active carbamazepine-10,11-epoxide, which is further hydrolyzed to inactive carbamazepine-10, 11-trans-dihydrodiol, and conjugated products which are finally excreted in urine. Carbamazepine is almost completely transformed by metabolism with less than 5% of a dose excreted unchanged [66]. Still, glucuronide conjugates of carbamazepine can presumably be cleaved during wastewater treatment, so its environmental concentrations increase [27]. In fact, carbamazepine and its metabolites have been detected in both wastewaters and biosolids [67].

Carbamazepine is heavily or not degraded during wastewater treatment and many studies have found it ubiquitous in various environment matrices (groundwater, river, soil) [34, 62, 68–71]. The concentrations of carbamazepine vary from one plant to another, and they are usually around hundreds ng/L, and in some cases also few µg/L [27, 72].

3.2 Occurrence of Pharmaceuticals in Sewage Sludge

Sludge, originating from the wastewater treatment processes, is the semisolid residue generated during the primary (physical and/or chemical), the secondary (biological), and the tertiary (often nutrient removal) treatment. In the last years the quantities of sludge have been increasing in EU because of the implementation of the Directive 91/271/EEC on urban wastewater treatment. There was nearly nine million tons of dry matter produced in 2005 in EU Member states. Similar regulation in USA was introduced by US EPA regulations 40 Code of Federal Regulations Part 503 (40 CFR 503) that established the minimum national standards for the use and disposal of domestic sludge. By this regulation, sludge was classified into two different microbiological types according to the extent of pathogen removal achieved by the sludge treatment process, i.e., Class A (usage without end-use restrictions) and Class B (controlled/limited disposal). The amount of sludge generated in 2006 was estimated to be more than eight million tons of which 50% were land applied [73].

Due to the physical–chemical processes involved in the treatment, the sludge tends to concentrate heavy metals and poorly biodegradable trace organic compounds as well as potentially pathogenic organisms (viruses, bacteria, etc.) present in waste waters. Sludge is, however, rich in nutrients such as nitrogen and phosphorous and contains valuable organic matter that is useful when soils are depleted or subject to erosion. It has been used in agriculture over a long time. In EU, since 1986, the utilization of sewage sludge has been ruled by the EU Directive (86/278/EEC), which encouraged the use of sludge regulating its use with respect to the quality of sludge, the soil on which it is to be used, the loading rate, and the crops that may be grown on treated land. None of the regulations cover the question of pharmaceuticals and other emerging pollutants that may be transported to soil after land application of biosolids, having the potential to enter surface water, leach into groundwater, or be accumulated by vegetation or other living organisms.

Most of the studies on the fate of pharmaceuticals in WWTPs focused only on the aqueous phase, and concentrations of the compounds in sludge were rarely determined mainly due to the demanding efforts required in the analysis in this difficult matrix. Out of 117 publications studied by Miege et al. [19], only 15 reported the concentrations of pharmaceuticals in sludge and 1 in suspended solid, and none of these papers reported the removal obtained taking into account both aqueous and solid phases of WWTPs. Still, the screening of sewage sludge showed that these micropollutants are very present in this medium [74–77]. High aqueous-phase removal rates for some compounds would suggest very good removal of

these compounds during the wastewater treatment. But only a certain percent of the total mass of input is really lost (i.e., biodegraded) during the treatment. The rest accumulates in sludge or ends up discharged with the effluent. As shown in Fig. 4, sorption of some pharmaceuticals analyzed in the study of Jelic et al. [20]




Fig. 4 Normalized mass loads of the selected pharmaceuticals entering three studied WWTPs, i.e., fraction discharged with effluent, sorbed to sludge, and removed during treatment

(e.g., atorvastatin, clarithromycin) contributed to the elimination from the aqueous phase with more than 20% related to the amount of these compounds at the influent. In the figure, term *liquid removal* indicates a difference in the loads of pharmaceuticals between influent and effluent wastewater, and *overall removal*, a difference in the loads that enter (i.e., influent) and exit (including both effluent and sludge loads) the plants. The difference between overall and liquid removal is the fraction that sorbed to sludge matter. This example clearly indicates the importance of the analysis of sludge when studying wastewater treatment performances.

The sorption behavior of pharmaceuticals can be very complex and difficult to assess. These compounds can absorb onto bacterial lipid structure and fat fraction of the sewage sludge through hydrophobic interactions (e.g., aliphatic and aromatic groups), adsorb onto often negatively charged polysaccharide structures on the outside of bacterial cells through electrostatic interactions (e.g., amino groups), and/or they can bind chemically to bacterial proteins and nucleic acids [78]. Also the mechanisms other than hydrophobic partitioning, such as hydrogen bonding, ionic interactions, and surface complexation, play a significant role in the sorption of pharmaceuticals in sludge. Therefore, also the compounds with low $\text{Log}K_{ow}$ and $\text{Log}K_d$ values may easily sorb onto sludge. Despite their negative K_{ow} , fluoroquinolones have a high tendency for sorption because of their zwitterionic character ($\text{p}K_{aCOOH} = 5.9 - 6.4$, $\text{p}K_{aNH_2} = 7.7 - 10.2$) [49]. These antibiotics were reported to be present in the highest concentration in sewage sludge samples from various WWTPs [50, 74, 79]. Also tetracycline and sulfonamides exhibit strong sorption onto sludge particles, higher than expected based on their hydrophobicity.

In general, data on the occurrence of pharmaceuticals in sludge are sparse, where the group of antibiotics was mostly analyzed and found to be the most abundant. Kinney et al. [7] measured erythromycin- H_2O , sulfamethoxazole, and trimethoprim in microgram per kilogram concentrations in nine different biosolids. Out of the 72 pharmaceuticals and personal care products targeted in the study of EPA in its 2001




Fig. 5 Concentrations of the pharmaceuticals in sludge (25th, median, and 75th percentile, for the values found in the literature)

National Sewage Sludge Survey, 38 (54%) were detected at concentrations ranging from the low ng/g to the µg/g range. All the analyzed antibiotics constituted about 29% of the total mass of pharmaceuticals per sample [76]. Only few studies reported data on the occurrence of anti-inflammatories and some other therapeutic classes (psychoactive drugs, lipid-lowering drugs, etc.) [20, 79–82]. Figure 5 summarizes some literature data on the occurrence of several pharmaceuticals in sewage sludge in various WWTPs.

4 Removal of Pharmaceuticals During Conventional Wastewater Treatment

Municipal wastewater treatment plants were basically designed to remove pathogens and organic and inorganic suspended and flocculated matter. Even though the new treatment technologies have been developed to deal with health and environmental concerns associated with findings of nowadays research, the progress was not as enhanced as the one of the analytical detection capabilities and the pharmaceutical residues remain in the output of WWTPs. When speaking about pharmaceuticals, the term *removal* refers to the conversion of a pharmaceutical to a compound different than the analyzed one (i.e., the parent compound). Thus, it accounts for all the losses of a parent compound produced by different mechanisms of chemical and physical transformation, biodegradation, and sorption to solid matter. All these processes (mainly biodegradation, sorption, and photodegradation) are limited in some way for the following reasons: (a) pharmaceuticals are designed to be biologically stable; (b) the sorption depends on the type and properties of the suspended solids (sludge); (c) and even though they are photoactive, because many of them have aromatic rings, heteroatoms, and other functional groups that could be susceptible to photodegradation; they may also give the products of environmental concern.

Removal, as difference in the loads between influent and effluent, has negative values in some cases. The explanation for this could be found in sampling protocols [83], not only because they could be inadequate, but because of the nature of disposal of pharmaceuticals. The fact is that the substances arrive in a small number of wastewater packets to the influent of WWTP, in unpredictable amounts and time intervals; thus the influent loads, especially, are easily systematically underestimated.

Even though the analysis of effluent and sludge yields more certain results, because they come from stabilization processes, the sampling in general may result in underestimated and even negative removals. Furthermore, the negative removal can be explained by the formation of unmeasured products of human metabolism and/or transformation products (e.g., glucuronide conjugate, methylates, and glycines) that passing through the plant convert back to the parent compounds. This can be considered as a reasonable assumption since the metabolites and some derivatives of pharmaceuticals are well known (e.g., hydroxy and epoxy-derivatives of carbamazepine, 4-trans-hydroxy and 3-cis-hydroxy derivatives of glibenclamide,

ortho- and parahydroxylated derivatives of atorvastatin, etc.) [67, 84, 85]. During complex metabolic processes in human body and biochemical in wastewater treatment, various scenarios of transformation from parent compound to metabolite and derivatives and vice versa can occur. Generally speaking, metabolites tend to increase the water solubility of the parent compound. Two different strategies are followed to achieve that objective: chemical modification of the parent molecule through addition of polar groups like OH, COOH, etc.; alternatively, the parent structures can be linked reversibly to polar highly soluble biological molecules, such as glucuronic acid, forming the so-called conjugates. Metabolites can be just as active as their parent compounds. Therefore, the occurrence of metabolites and transformation products and pathways should be included in the future studies in order to obtain accurate information on the removal of pharmaceuticals during treatment and to determine treatment plant capabilities.

The extent to which one compound can be removed during wastewater treatment is influenced by chemical and biological properties of the compound, but also of wastewater characteristics, operational conditions, and treatment technology used. Therefore, as shown in the following examples, high variations in elimination may be expected, and no clear and definitive conclusion can be made on the removal of any particular compound, and even less on the fate of a therapeutic group. Some operating parameters such as hydraulic retention time (HRT), solid retention time (SRT), redox conditions, and temperature may affect removal of pharmaceuticals during conventional treatment [127]. Of all the operating parameters, SRT is the most critical parameter for activated sludge design as SRT affects the treatment process performance, aeration tank volume, sludge production, and oxygen requirements. It has been proved that longer SRT, especially, influences and improves the elimination of most of the pharmaceuticals during sewage treatment [43, 68, 86]. WWTPs with high SRTs allow the enrichment of slowly growing bacteria and consequently the establishment of a more diverse biocoenosis with broader physiological capabilities (e.g., nitrification or the capability for certain elimination pathways) than WWTPs with low SRTs [68].

NSAIDs have been the most studied group in terms of both occurrence and removal during wastewater treatment. As noted, the pharmaceuticals are grouped according to the therapeutic applications; thus high variations in removal rates were observed within the group due to the differences in chemical properties. While ibuprofen and naproxen are generally removed with very high efficiency, diclofenac is only barely removable during conventional treatment. The removal rates of ibuprofen and naproxen are commonly higher than 75% and 50%, respectively [87–92]. Diclofenac shows rather low and very inconsistent removal rates, between 0 and 90% [88, 89, 91, 92]. Its persistence is attributed to the presence of chlorine group in the molecule. Some studies on removal during wastewater treatment showed no influence of SRT on the removal of diclofenac [68, 93, 94]. The removal of ibuprofen, ketoprofen, indomethacin, acetaminophen, and mefenamic acid is reported to be very high (>80%) or even complete for SRT typical for nutrient removal ($10 < \text{SRT} < 20$ days) [88, 90, 94].

Beta-blockers were reported to be only partially eliminated by conventional biological treatment [128, 26, 27, 31]). The data on their removal are very inconsistent and the removal rates vary from less than 10% up to 95% depending on the treatment. Maurer et al. proved that the elimination of beta-blockers in WWTPs depends on the HRT, which could be a good explanation for the variable removal reported in the literature. The highest average elimination rates can be observed for atenolol and sotalol (around 60%). But for the same compounds low removals were reported as well. Maurer et al. [95] and Wick et al. [96] reported removal rates lower than 30% for sotalol, and Castiglioni et al. [87] reported a removal of 10% for atenolol during the winter months. In the same study, atenolol achieved better elimination in summer (i.e., 55%) due to a higher microbial activity [87]. In most cases, metoprolol showed very low removal rates, i.e., 10–30% [26, 31, 97]. The occurrence and microbial cleavage of conjugates are well known to influence the mass balance in WWTPs [98–100]. The microbial cleavage of conjugates of metoprolol could be responsible for an underestimation of its removal efficiency. For propranolol as well, various removal rates, mostly moderately low [96, 101], were observed. This compound is by far the most lipophilic beta-blocker and the only one with a bioaccumulation potential. Sludge–water partition coefficients were found to be less than 100 L/kg_{ss} for sotalol and atenolol, and 343 L/kg_{ss} for propranolol [95]. For $K_{d,s}$ values less than 500 L/kg_{ss} the removal by sorption in a WWTP with a typical sludge production of 0.2 g_{ss}/L is less than 10% [102] and hence does not significantly contribute to the removal of beta-blockers in activated sludge units [96]. Therefore, the partial removal of beta-blockers can be assumed to be due to biotransformation.

No significant to medium removal was reported for all the *lipid regulators*. Zorita et al. [22] reported a medium removal of 61% during primary and biological treatment, where during the latter one no removal was observed. Lower removal rates were reported by some other authors, <35% [87, 103, 104]. No or low removal of clofibric acid was observed in different WWTPs of Berlin [105]. Winkler et al. [106] found no evidence for biotic degradation of clofibric acid. Radjenovic et al. [36] showed that clofibric acid may be removed more efficiently with MBR (72–86%) compared to the activated sludge process (of 26–51%). The removal rates of fibrates bezafibrate, fenofibrate, and gemfibrozil vary between 30 and 90% [88, 94, 107]. Various removal rates during biological treatment in ten WWTPs in Spain were reported in the studies of Jelić et al. [20] and Gros et al. [30]. It was found that sorption to sludge particulate contributes to the removal values with ca. 20% [20].

Results from various studies showed that *anticonvulsant carbamazepine* is recalcitrant to biological treatment and it is not removed during either conventional wastewater treatment or membrane bioreactor treatments [34, 62, 69, 71, 91, 108]. Physicochemical processes such as coagulation-flocculation and flotation did not give better results concerning its degradation [109–111]. It was constantly found at higher concentrations at the effluent of WWTPs. Knowing that the activated sludge has glucuronidase activity, which allows the cleavage of the glucorinic acid moiety in WWTP [112], rational explanation for the increase in concentration is conversion

of CBZ glucuronides and other conjugated metabolites to the parent compound by enzymatic processes in a WWTP. No influence of SRT on the removal of CBZ during conventional wastewater treatment was noticed [68, 93]. Except for carbamazepine, information on the occurrence and fate of other psychoactive drugs in WWTPs is very scarce. This is probably because of the low therapeutic dose resulting generally in low concentrations in the environment [63, 113, 114]. Conventional treatment achieves a removal lower than 10% in case of diazepam [72]. Zorita et al. [22] reported very high removal efficiency in case of fluoxetine and its active metabolite norfluoxetine. Still, the lowest observed effect concentration of fluoxetine for zooplankton and benthic organisms is close to the maximal measured WWTP effluent concentrations [115]. Low effluent concentrations can be due to the fact that fluoxetine rapidly passes to solid phase where it appears to be very persistent [116, 117]. Additionally, it was found that it has a high bioaccumulation potential when detected in wild fish [118].

The removal of several other drugs such as the *histamine H2-receptor antagonists* cimetidine, famotidine, and ranitidine varied from low to very high. Radjenovic et al. [36] reported rather poor and unstable removal of histamines during conventional treatment (15–60%). Castiglioni et al. [87] found that the removal of ranitidine depends on season, and showed 39% removal in winter and 84% in summer. High removal of ranitidine during activate sludge treatment (89%) was observed in a study of Kasprzyk-Hordern et al. [21].

Antibiotics cover a broad range of chemical classes, and it is very difficult to characterize their behavior during activated sludge process due to varying removal efficiencies reported from studies undertaken worldwide. Due to their limited biodegradability and sorption properties, sulfonamides and trimethoprim appear to be only partially removed by conventional wastewater treatment. The removal of these antibiotics has been reported to vary significantly [41–44, 97, 119]. The explanation could be found in different operational parameters such as HRT, SRT, and temperature and also in the fact that sulfonamides are easily transformed from their parent compounds to their metabolites and vice versa; thus the removal efficiencies may be easily or underestimated or overestimated. In case of trimethoprim, only minor removal was noticed during primary and biological treatment, but the advanced treatment [43] and nitrification organisms appear to be capable of degrading trimethoprim [120, 121]. This suggests an important role for aerobic conditions for the biotransformation of trimethoprim. Consistent with this, removal efficiency of trimethoprim appears to be enhanced by long SRT during biological treatment, which is conducive to nitrification [122]. Also macrolide antibiotics are often incompletely removed during biological wastewater treatment. Studies from different conventional WWTPs have revealed that the removal of macrolides varied from high but negative values, to around 50% [43, 88]. Karthikeyan and Meyer [59] found that 43 to 99% of erythromycin was removed by activated sludge process and aerated lagoons. In the study of Kobayashi et al. [123], 50% of clarithromycin and azithromycin were removed from three conventional WWTPs. Gobel et al. [43] proposed gradual release of the macrolides (e.g., clarithromycin) from feces particles during biological treatment as an explanation for the possible negative

removal rates for these antibiotics. Sorption of macrolides to wastewater biomass is attributed to hydrophobic interactions (high partitioning coefficient). But knowing that the surface of activated sludge is predominantly negatively charged, and under typical wastewater conditions, the basic dimethylamino group ($pK_a > 8.9$) is protonated, sorption could occur due to cation exchange interaction as well [124]. Greater adsorption of azithromycin to biomass compared to clarithromycin has been reported [123]. Varying removal was reported for fluoroquinolone antibiotics, as well. [125] found that norfloxacin and ciprofloxacin were removed with 78% and 80%, respectively, where around 40% was removed during the biological treatment. Similar removal was reported by Zorita et al. [22] during secondary and tertiary treatment. The predominant removal mechanism of fluoroquinolones has been suggested to be adsorption to sludge and/or flocs rather than biodegradation [22, 49, 122, 125]. Ciprofloxacin and norfloxacin sorbed to sludge independently of changes in pH during wastewater treatment, and more than 70% of the total amount of these compounds passing through the plant was ultimately found in the digested sludge [125]. These findings indicated sludge as the main reservoir of fluoroquinolones that may potentially release the antibiotics into the environment when applied to agricultural land. Karthikeyan and Meyer [59] reported removal efficiency of 68% for tetracycline, and Yang et al. [45] have reported removals of 78 and 67% for chlortetracycline and doxycycline, respectively, during activated sludge processes. Also some tetracyclines have significant potential for absorption onto solids due to a combination of non-hydrophobic mechanisms, such as ionic interactions, metal complexation, hydrogen bond formation, or polarization [126]. Their removal is not so affected by HRT, but SRT appears to significantly influence the removal during biological treatment [53].

5 Conclusion

Various studies showed that even though the conventional WWTPs meet the regulatory requirements for wastewater treatment (Directive 91/271/EEC), they are only moderately effective in removing pharmaceuticals. The removal of pharmaceuticals will naturally depend on their chemical and biological properties, but also on wastewater characteristics, operational conditions, and treatment technology used. Thus, high variations in removal may be expected, and no clear and definitive conclusion can be made on the removal of any particular compound. Of all the operating parameters, the solid retention time (SRT) is the most critical parameter for activated sludge process and it has been proved that longer SRT improves the elimination of most of the pharmaceuticals during sewage treatment. Estimation of removal rates may be underestimated due to at least three factors: removal efficiency was calculated from the mean concentration values; the metabolites and transformation products of pharmaceuticals and their amounts were not defined; and the time-proportional sampling may not be perfectly suitable for pharmaceutical analysis, especially on influent. Still, the fact is that a number of

pharmaceuticals were detected in effluent wastewater and sludge samples. These pharmaceuticals cover a wide range of physical-chemical properties and biological activities. Although the chronic toxicity effects of such a mixture are unknown and thus the risk that it could pose to the environment could not be fully assessed, their presence must not be ignored. More information on quality, quantity, and toxicity of pharmaceuticals and their metabolites is definitely needed especially when attempting to reuse wastewater and dispose sludge to agricultural areas and landfills.

References

1. Daughton CG (2003) Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. I. Rational for and avenues toward a green pharmacy. *Environ Health Perspect* 111:757–774
2. Ruhoya ISR, Daughton CG (2008) Beyond the medicine cabinet: an analysis of where and why medications accumulate. *Environ Int* 34:1157–1169
3. Bartelt-Hunt SL, Snow DD, Damon T, Shockley J, Hoagland K (2009) The occurrence of illicit and therapeutic pharmaceuticals in wastewater effluent and surface waters in Nebraska. *Environ Pollut* 157:786–791
4. Nilsen EB, Rosenbauer RR, Furlong ET, Burkhardt MR, Werner SL, Greaser L, Noriega M (2007) Pharmaceuticals, personal care products and anthropogenic waste indicators detected in streambed sediments of the lower Columbia River and selected tributaries, National Ground Water Association, Paper 4483, p 15
5. Vazquez-Roig P, Segarra R, Blasco C, Andreu V, Picó Y (2010) Determination of pharmaceuticals in soils and sediments by pressurized liquid extraction and liquid chromatography tandem mass spectrometry. *J Chromatogr A* 1217:2471–2483
6. Gielen GJHP, Heuvel MRvd, Clinton PW, Greenfield LG (2009) Factors impacting on pharmaceutical leaching following sewage application to land. *Chemosphere* 74:537–542
7. Kinney CA, Furlong ET, Werner SL, Cahill JD (2006) Presence and distribution of wastewater-derived pharmaceuticals in soil irrigated with reclaimed water. *Environ Toxicol Chem* 25:317–326
8. Ternes TA, Bonerz M, Herrmann N, Teiser B, Andersen HR (2007) Irrigation of treated wastewater in Braunschweig, Germany: an option to remove pharmaceuticals and musk fragrances. *Chemosphere* 66:894–904
9. Carbonell G, Pro J, Gómez N, Babín MM, Fernández C, Alonso E, Tarazona JV (2009) Sewage sludge applied to agricultural soil: ecotoxicological effects on representative soil organisms. *Ecotoxicol Environ Saf* 72:1309–1319
10. Lapen DR, Topp E, Metcalfe CD, Li H, Edwards M, Gottschall N, Bolton P, Curnoe W, Payne M, Beck A (2008) Pharmaceutical and personal care products in tile drainage following land application of municipal biosolids. *Sci Total Environ* 399:50–65
11. Cleuvers M (2004) Mixture toxicity of the anti-inflammatory drugs diclofenac, ibuprofen, naproxen, and acetylsalicylic acid. *Ecotoxicol Environ Saf* 59:309–315
12. Nentwig G, Oetken M, Oehlmann J (2004) Effects of pharmaceuticals on aquatic invertebrates—the example of carbamazepine and clofibric acid. In: Kümmerer K (ed) *Pharmaceuticals in the environment. Sources, fate, effects and risks*, 2nd edn. Springer, Berlin, pp 195–207
13. Schnell S, Bols NC, Barata C, Porte C (2009) Single and combined toxicity of pharmaceuticals and personal care products (PPCPs) on the rainbow trout liver cell line RTL-W1. *Aquat Toxicol* 93:244–252

14. Metcalf and Eddy Inc (2003) Wastewater engineering – treatment and reuse, 4th edn. Tata McGraw Hill, New Delhi
15. Khetan SK, Collins TJ (2007) Human pharmaceuticals in the aquatic environment: a challenge to green chemistry. *Chem Rev* 107:2319–2364
16. Larsson DGJ, de Pedro C, Paxeus N (2007) Effluent from drug manufactures contains extremely high levels of pharmaceuticals. *J Hazard Mater* 148:751–755
17. Li D, Yang M, Hu J, Ren L, Zhang Y, Li K (2008) Determination and fate of oxytetracycline and related compounds in oxytetracycline production wastewater and the receiving river. *Environ Toxicol Chem* 27:80–86
18. Li D, Yang M, Hu J, Zhang Y, Chang H, Jin F (2008) Determination of penicillin G and its degradation products in a penicillin production wastewater treatment plant and the receiving river. *Water Res* 42:307–317
19. Miège C, Choubert JM, Ribeiro L, Eusèbe M, Coquery M (2009) Fate of pharmaceuticals and personal care products in wastewater treatment plants - Conception of a database and first results. *Environ Pollut* 157:1721–1726
20. Jelić A, Gros M, Ginebreda A, Cespedes-Sánchez R, Ventura F, Petrovic M, Barceló D (2011) Occurrence, partition and removal of pharmaceuticals in sewage water and sludge during wastewater treatment. *Water Res* 45:1165–1176
21. Kasprzyk-Hordern B, Dinsdale RM, Guwy AJ (2009) The removal of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs during wastewater treatment and its impact on the quality of receiving waters. *Water Res* 43:363–380
22. Zorita S, Mårtensson L, Mathiasson L (2009) Occurrence and removal of pharmaceuticals in a municipal sewage treatment system in the south of Sweden. *Sci Total Environ* 407:2760–2770
23. Heberer T, Reddersen K, Mechlinski A (2002) From municipal sewage to drinking water: fate and removal of pharmaceutical residues in the aquatic environment in urban areas. *Water Sci Technol* 46:81
24. Escher BI, Bramaz N, Richter M, Lienert J (2006) Comparative ecotoxicological hazard assessment of beta-blockers and their human metabolites using a mode-of-action-based test battery and a QSAR approach†. *Environ Sci Technol* 40:7402–7408
25. Ramil M, El Aref T, Fink G, Scheurer M, Ternes TA (2009) Fate of beta blockers in aquatic-sediment systems: sorption and biotransformation. *Environ Sci Technol* 44:962–970
26. Lee H-B, Sarafin K, Peart TE (2007) Determination of [beta]-blockers and [beta]2-agonists in sewage by solid-phase extraction and liquid chromatography-tandem mass spectrometry. *J Chromatogr A* 1148:158–167
27. Ternes TA (1998) Occurrence of drugs in German sewage treatment plants and rivers. *Water Res* 32:3245
28. Vieno N, Tuhkanen T, Kronberg L (2007) Elimination of pharmaceuticals in sewage treatment plants in Finland. *Water Res* 41:1001–1012
29. Bendz D, Paxéus NA, Ginn TR, Loge FJ (2005) Occurrence and fate of pharmaceutically active compounds in the environment, a case study: Höje River in Sweden. *J Hazard Mater* 122:195–204
30. Gros M, Petrovic M, Ginebreda A, Barceló D (2010) Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes. *Environ Int* 36:15–26
31. Vieno NM, Tuhkanen T, Kronberg L (2006) Analysis of neutral and basic pharmaceuticals in sewage treatment plants and in recipient rivers using solid phase extraction and liquid chromatography-tandem mass spectrometry detection. *J Chromatogr A* 1134:101–111
32. Health, U.S. (2010) Health, United States, 2009: with special feature on medical technology. National Center for Health Statistics, Hyattsville, MD
33. Gracia-Lor E, Sancho JV, Hernández F (2010) Simultaneous determination of acidic, neutral and basic pharmaceuticals in urban wastewater by ultra high-pressure liquid chromatography-tandem mass spectrometry. *J Chromatogr A* 1217:622–632

34. Metcalfe CD, Koenig BG, Bennie DT, Servos M, Ternes TA, Hirsch R (2003) Occurrence of neutral and acidic drugs in the effluents of Canadian sewage treatment plants. *Environ Toxicol Chem* 22:2872–2880
35. Miao X-S, Metcalfe CD (2003) Determination of cholesterol-lowering statin drugs in aqueous samples using liquid chromatography-electrospray ionization tandem mass spectrometry. *J Chromatogr A* 998:133–141
36. Radjenovic J, Petrovic M, Barceló D (2009) Fate and distribution of pharmaceuticals in wastewater and sewage sludge of the conventional activated sludge (CAS) and advanced membrane bioreactor (MBR) treatment. *Water Res* 43:831–841
37. Kümmerer K (2003) Significance of antibiotics in the environment. *J Antimicrob Chemother* 52:5–7
38. Huang CH, Renew JE, Smeby KL, Pinkerston K, Sedlak DL (2001) Assessment of potential antibiotic contaminants in water and preliminary occurrence analysis. *Water Resour Update* 120:30–40
39. Jones OAH, Voulvoulis N, Lester JN (2004) Potential ecological and human health risks associated with the presence of pharmaceutically active compounds in the aquatic environment. *Crit Rev Toxicol* 34:335–350
40. Le-Minh N, Khan SJ, Drewes JE, Stuetz RM (2010) Fate of antibiotics during municipal water recycling treatment processes. *Water Res* 44:4295–4323
41. Brown KD, Kulis J, Thomson B, Chapman TH, Mawhinney DB (2006) Occurrence of antibiotics in hospital, residential, and dairy effluent, municipal wastewater, and the Rio Grande in New Mexico. *Sci Total Environ* 366:772–783
42. Choi K-J, Kim S-G, Kim C-W, Kim S-H (2007) Determination of antibiotic compounds in water by on-line SPE-LC/MSD. *Chemosphere* 66:977–984
43. Göbel A, McArdell CS, Joss A, Siegrist H, Giger W (2007) Fate of sulfonamides, macrolides, and trimethoprim in different wastewater treatment technologies. *Sci Total Environ* 372:361–371
44. Levine AD, Meyer MT, Kish G (2006) Evaluation of the persistence of micropollutants through pure-oxygen activated sludge nitrification and denitrification. *Water Environ Res* 78:2276–2285
45. Yang S, Cha J, Carlson K (2005) Simultaneous extraction and analysis of 11 tetracycline and sulfonamide antibiotics in influent and effluent domestic wastewater by solid-phase extraction and liquid chromatography-electrospray ionization tandem mass spectrometry. *J Chromatogr A* 1097:40–53
46. Peng X, Wang Z, Kuang W, Tan J, Li K (2006) A preliminary study on the occurrence and behavior of sulfonamides, ofloxacin and chloramphenicol antimicrobials in wastewaters of two sewage treatment plants in Guangzhou, China. *Sci Total Environ* 371:314–322
47. Göbel A, Thomsen A, McArdell CS, Joss A, Giger W (2005) Occurrence and Sorption Behavior of Sulfonamides, Macrolides, and Trimethoprim in Activated Sludge Treatment. *Environ Sci Technol* 39:3981–3989
48. Watkinson AJ, Murby EJ, Costanzo SD (2007) Removal of antibiotics in conventional and advanced wastewater treatment: Implications for environmental discharge and wastewater recycling. *Water Res* 41:4164–4176
49. Golet EM, Xifra I, Siegrist H, Alder AC, Giger W (2003) Environmental exposure assessment of fluoroquinolone antibacterial agents from sewage to soil. *Environ Sci Technol* 37:3243
50. Lindberg RH, Wennberg P, Johansson MI, Tysklind M, Andersson BAV (2005) Screening of human antibiotic substances and determination of weekly mass flows in five sewage treatment plants in Sweden. *Environ Sci Technol* 39:3421–3429
51. Alder AC, McArdell CS, Golet EM, Ibric S, Molnar E, Nipales NS, Giger W (2001) Occurrence and fate of fluoroquinolone, macrolide, and sulfonamide antibiotics during wastewater treatment and in ambient waters in Switzerland. In: Daughton CG, Jones-Lepp TM (eds) *Pharmaceuticals and personal care products in the environment, scientific and regulatory*

- issues, American Chemical Society Symposium Series 791. American Chemical Society, Washington, DC, pp 56–69
52. Golet EM, Alder AC, Hartmann A, Ternes TA, Giger W (2001) Trace determination of fluoroquinolone antibacterial agents in urban wastewater by solid-phase extraction and liquid chromatography with fluorescence detection. *Anal Chem* 73:3632
 53. Kim S, Eichhorn P, Jensen JN, Weber AS, Aga DS (2005) Removal of antibiotics in wastewater: effect of hydraulic and solid retention times on the fate of tetracycline in the activated sludge process. *Environ Sci Technol* 39:5816–5823
 54. Yang S, Carlson K (2003) Evolution of antibiotic occurrence in a river through pristine, urban and agricultural landscapes. *Water Res* 37:4645–4656
 55. Alexy R, Kümpe T, Kümmerer K (2004) Assessment of degradation of 18 antibiotics in the Closed Bottle Test. *Chemosphere* 57:505–512
 56. Daughton CG, Ternes TA (1999) Pharmaceuticals and personal care products in the environment: Agents of subtle change? *Environ Health Perspect* 107:907–938
 57. Göbel A, Thomsen A, McArdell CS, Alder AC, Giger W, Theiß N, Loeffler D, Ternes TA (2005) Extraction and determination of sulfonamides, macrolides, and trimethoprim in sewage sludge. *J Chromatogr A* 1085:179–189
 58. Gulkowska A, Leung HW, So MK, Taniyasu S, Yamashita N, Yeung LWY, Richardson BJ, Lei AP, Giesy JP, Lam PKS (2008) Removal of antibiotics from wastewater by sewage treatment facilities in Hong Kong and Shenzhen, China. *Water Res* 42:395–403
 59. Karthikeyan KG, Meyer MT (2006) Occurrence of antibiotics in wastewater treatment facilities in Wisconsin, USA. *Sci Total Environ* 361:196–207
 60. Hirsch R, Ternes T, Haberer K, Kratz KL (1999) Occurrence of antibiotics in the aquatic environment. *Sci Total Environ* 225:109
 61. Richardson SD (2010) Environmental mass spectrometry: emerging contaminants and current issues. *Anal Chem* 82:4742–4774
 62. Radjenovic J, Petrovic M, Barceló D (2007) Analysis of pharmaceuticals in wastewater and removal using a membrane bioreactor. *Anal Bioanal Chem* 387:1365–1377
 63. Kolpin DW, Furlong ET, Meyer MT, Thurman EM, Zaugg SD, Barber LB, Buxton HT (2002) Pharmaceuticals and other organic wastewater contaminants in US streams, 1999–2000: a national reconnaissance. *Environ Sci Technol* 36:1202
 64. Fertig EJ, Mattson RH (2008) Carbamazepine in the book: Epilepsy: A comprehensive textbook, vol 2. Lippincott Williams and Wilkins, Philadelphia, PA, pp 1543–1556
 65. Yoshimura R, Yanagihara N, Terao T, Minami K, Toyohira Y, Ueno S, Uezono Y, Abe K, Izumi F (1998) An active metabolite of carbamazepine, carbamazepine-10,11-epoxide, inhibits ion channel-mediated catecholamine secretion in cultured bovine adrenal medullary cells. *Psychopharmacology* 135:368–373
 66. Shorvon S, Perucca E, Fish D, Dodson E (2004) Carbamazepine in: the treatment of epilepsy. Blackwell Science, Maiden, MA, pp 131–132
 67. Miao X-S, Yang J-J, Metcalfe CD (2005) Carbamazepine and its metabolites in wastewater and in biosolids in a municipal wastewater treatment plant. *Environ Sci Technol* 39:7469–7475
 68. Clara M, Kreuzinger N, Strenn B, Gans O, Kroiss H (2005) The solids retention time – a suitable design parameter to evaluate the capacity of wastewater treatment plants to remove micropollutants. *Water Res* 39:97–106
 69. Clara M, Strenn B, Kreuzinger N (2004) Carbamazepine as a possible anthropogenic marker in the aquatic environment: investigations on the behaviour of Carbamazepine in wastewater treatment and during groundwater infiltration. *Water Res* 38:947–954
 70. Joss A, Keller E, Alder AC, Gbel A, McArdell CS, Ternes T, Siegrist H (2005) Removal of pharmaceuticals and fragrances in biological wastewater treatment. *Water Res* 39:3139
 71. Zhang Y, Geißen S-U, Gal C (2008) Carbamazepine and diclofenac: removal in wastewater treatment plants and occurrence in water bodies. *Chemosphere* 73:1151–1161

72. Ternes TA, Janex-Habibi M-L, Knacker T, Kreuzinger N, Siegrist H (2005) Assessment of technologies for the removal of pharmaceuticals and personal care products in sewage and drinking water facilities – POSEIDON Project
73. Kinney CA, Furlong ET, Kolpin DW, Burkhardt MR, Zaugg SD, Werner SL, Bossio JP, Benotti MJ (2008) Bioaccumulation of pharmaceuticals and other anthropogenic waste indicators in earthworms from agricultural soil amended with biosolid or swine manure. *Environ Sci Technol* 42:1863–1870
74. Lillenberg M, Yurchenko S, Kipper K, Herodes K, Pihl V, Sepp K, Löhmus R, Nei L (2009) Simultaneous determination of fluoroquinolones, sulfonamides and tetracyclines in sewage sludge by pressurized liquid extraction and liquid chromatography electrospray ionization-mass spectrometry. *J Chromatogr A* 1216:5949–5954
75. Lindberg RH, Fick J, Tysklind M (2010) Screening of antimycotics in Swedish sewage treatment plants – Waters and sludge. *Water Res* 44:649–657
76. McClellan K, Halden RU (2010) Pharmaceuticals and personal care products in archived U.S. biosolids from the, 2001 EPA national sewage sludge survey. *Water Res* 44:658–668
77. Radjenovic J, Jelic A, Petrovic M, Barcelo D (2009) Determination of pharmaceuticals in sewage sludge by pressurized liquid extraction (PLE) coupled to liquid chromatography-tandem mass spectrometry (LC-MS/MS). *Anal Bioanal Chem* 393:1685–1695
78. Meakins NC, Bubbs JM, Lester JN (1994) Fate and behaviour of organic micropollutants during wastewater treatment processes: a review. *Int J Environ Pollut* 4:27–58
79. Chenxi W, Sponberg AL, Witter JD (2008) Determination of the persistence of pharmaceuticals in biosolids using liquid-chromatography tandem mass spectrometry. *Chemosphere* 73:511–518
80. Nieto A, Borrull F, Marcé RM, Pocurull E (2007) Selective extraction of sulfonamides, macrolides and other pharmaceuticals from sewage sludge by pressurized liquid extraction. *J Chromatogr A* 1174:125–131
81. Okuda T, Yamashita N, Tanaka H, Matsukawa H, Tanabe K (2009) Development of extraction method of pharmaceuticals and their occurrences found in Japanese wastewater treatment plants. *Environ Int* 35:815–820
82. Sponberg AL, Witter JD (2008) Pharmaceutical compounds in the wastewater process stream in Northwest Ohio. *Sci Total Environ* 397:148–157
83. Ort C, Lawrence MG, Rieckermann Jr, Joss A (2010) Sampling for pharmaceuticals and personal care products (PPCPs) and illicit drugs in wastewater systems: are your conclusions valid? a critical review. *Environ Sci Technol* 44:6024–6035
84. Aviram M, Rosenblat M, Bisgaier CL, Newton RS (1998) Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. *Atherosclerosis* 138:271–280
85. Shipkova M, Wieland E (2005) Glucuronidation in therapeutic drug monitoring. *Clin Chim Acta* 358:2–23
86. Suárez S, Ramil M, Omil F, Lema JM (2005) Removal of pharmaceutically active compounds in nitrifying-denitrifying plants. *Water Sci Technol* 52:9–14
87. Castiglioni S, Bagnati R, Fanelli R, Pomati F, Calamari D, Zuccato E (2006) Removal of pharmaceuticals in sewage treatment plants in Italy. *Environ Sci Technol* 40:357–363
88. Clara M, Strenn B, Gans O, Martinez E, Kreuzinger N, Kroiss H (2005) Removal of selected pharmaceuticals, fragrances and endocrine disrupting compounds in a membrane bioreactor and conventional wastewater treatment plants. *Water Res* 39:4797
89. Gómez MJ, Martínez Bueno MJ, Lacorte S, Fernández-Alba AR, Agüera A (2007) Pilot survey monitoring pharmaceuticals and related compounds in a sewage treatment plant located on the Mediterranean coast. *Chemosphere* 66:993–1002
90. Jones OAH, Voulvoulis N, Lester JN (2005) Human pharmaceuticals in wastewater treatment processes. *Crit Rev Environ Sci Technol* 35:401–427
91. Joss A, Keller E, Alder AC, Göbel A, McArdell CS, Ternes T, Siegrist H (2005) Removal of pharmaceuticals and fragrances in biological wastewater treatment. *Water Res* 39:3139–3152

92. Lindqvist N, Tuhkanen T, Kronberg L (2005) Occurrence of acidic pharmaceuticals in raw and treated sewages and in receiving waters. *Water Res* 39:2219–2228
93. Kreuzinger N, Clara M, Strenn B, Kroiss H (2004) Relevance of the sludge retention time (SRT) as design criteria for wastewater treatment plants for the removal of endocrine disruptors and pharmaceuticals from wastewater. *Water Sci Technol* 50:149–156
94. Lishman L, Smyth SA, Sarafin K, Kleywegt S, Toito J, Peart T, Lee B, Servos M, Beland M, Seto P (2006) Occurrence and reductions of pharmaceuticals and personal care products and estrogens by municipal wastewater treatment plants in Ontario, Canada. *Sci Total Environ* 367:544–558
95. Maurer M, Escher BI, Richle P, Schaffner C, Alder AC (2007) Elimination of [beta]-blockers in sewage treatment plants. *Water Res* 41:1614–1622
96. Wick A, Fink G, Joss A, Siegrist H (2009) Fate of beta blockers and psycho-active drugs in conventional wastewater treatment. *Water Res* 43:1060–1074
97. Paxéus N (2004) Removal of selected non-steroidal anti-inflammatory drugs (NSAIDs), gemfibrozil, carbamazepine, β -blockers, trimethoprim and triclosan in conventional wastewater treatment plants in five EU countries and their discharge to the aquatic environment. *Water Sci Technol* 5:253–260
98. Andersen H, Siegrist H, Halling-Sørensen B, Ternes TA (2003) Fate of estrogens in a municipal sewage treatment plant. *Environ Sci Technol* 37:4021–4026
99. Belfroid AC, Van der Horst A, Vethaak AD, Schäfer AJ, Rijs GBJ, Wegener J, Cofino WP (1999) Analysis and occurrence of estrogenic hormones and their glucuronides in surface water and waste water in The Netherlands. *Sci Total Environ* 225:101–108
100. Ternes TA, Kreckel P, Mueller J (1999) Erratum: Behaviour and occurrence of estrogens in municipal sewage treatment plants – II. Aerobic batch experiments with activated sludge. *Sci Total Environ* 228:89–99
101. Alder AC, Bruchet A, Carballa M, Clara M, Joss A, Löffler D, McArdell CS, Miksch K, Omil F, Tuhkanen T, Ternes TA (2006) Consumption and occurrence. In: Ternes TA, Joss A (eds) *Human pharmaceuticals, hormones and fragrances*. IWA Publishing, London, pp 15–54
102. Ternes TA, Herrmann N, Bonerz M, Knacker T, Siegrist H, Joss A (2004) A rapid method to measure the solid-water distribution coefficient (K_d) for pharmaceuticals and musk fragrances in sewage sludge. *Water Res* 38:4075
103. Kosjek T, Heath E, Petrovic M, Barceló D (2007) Mass spectrometry for identifying pharmaceutical biotransformation products in the environment. *TrAC Trends Anal Chem* 26:1076–1085
104. Matamoros V, Caselles-Osorio A, García J, Bayona JM (2008) Behaviour of pharmaceutical products and biodegradation intermediates in horizontal subsurface flow constructed wetland. A microcosm experiment. *Sci Total Environ* 394:171–176
105. Heberer T (2002) Tracking persistent pharmaceutical residues from municipal sewage to drinking water. *J Hydrol* 266:175
106. Winkler M, Lawrence JR, Neu TR (2001) Selective degradation of ibuprofen and clofibrilic acid in two model river biofilm systems. *Water Res* 35:3197–3205
107. Ternes TA, Meisenheimer M, McDowell D, Sacher F, Brauch H Jr, Haist-Gulde B, Preuss G, Wilme U, Zulei-Seibert N (2002) Removal of pharmaceuticals during drinking water treatment. *Environ Sci Technol* 36:3855–3863
108. Miao X-S, Metcalfe CD (2003) Determination of carbamazepine and its metabolites in aqueous samples using liquid chromatography – electrospray tandem mass spectrometry. *Anal Chem* 75:3731–3738
109. Carballa M, Omil F, Lema JM, Llopart M, Garcia-Jares C, Rodriguez I, Gomez M, Ternes T (2004) Behaviour of pharmaceuticals, cosmetics and hormones in a sewage treatment plant. *Water Res* 38:2918
110. Reif R, Suárez S, Omil F, Lema JM (2008) Fate of pharmaceuticals and cosmetic ingredients during the operation of a MBR treating sewage. *Desalination* 221:511–517

111. Suárez S, Carballa M, Omil F, Lema JM (2008) How are pharmaceutical and personal care products (PPCPs) removed from urban wastewaters? *Rev Environ Sci Biotechnol* 7:125–138
112. Ternes TA, Kreckel P, Mueller J (1999) Behaviour and occurrence of estrogens in municipal sewage treatment plants – II. Aerobic batch experiments with activated sludge. *Sci Total Environ* 225:91–99
113. Kümmerer K (2004) *Pharmaceuticals in the environment: sources, fate effects and risks*. Springer, Berlin
114. Zorita S, Mårtensson L, Mathiasson L (2007) Hollow-fibre supported liquid membrane extraction for determination of fluoxetine and norfluoxetine concentration at ultra trace level in sewage samples. *J Sep Sci* 30:2513–2521
115. Fent K, Weston AA, Caminada D (2006) Ecotoxicology of human pharmaceuticals. *Aquat Toxicol* 76:122–159
116. Kwon J-W, Armbrust KL (2006) Laboratory persistence and fate of fluoxetine in aquatic environments. *Environ Toxicol Chem* 25:2561–2568
117. Redshaw C, Cooke M, Talbot H, McGrath S, Rowland S (2008) Low biodegradability of fluoxetine HCl, diazepam and their human metabolites in sewage sludge-amended soil. *J Soils Sedim* 8:217–230
118. Chu S, Metcalfe CD (2007) Analysis of paroxetine, fluoxetine and norfluoxetine in fish tissues using pressurized liquid extraction, mixed mode solid phase extraction cleanup and liquid chromatography-tandem mass spectrometry. *J Chromatogr A* 1163:112–118
119. Gros M, Petrovic M, Barceló D (2006) Development of a multi-residue analytical methodology based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for screening and trace level determination of pharmaceuticals in surface and wastewaters. *Talanta* 70:678–690
120. Batt AL, Bruce IB, Aga DS (2006) Evaluating the vulnerability of surface waters to antibiotic contamination from varying wastewater treatment plant discharges. *Environ Pollut* 142: 295–302
121. Pérez S, Eichhorn P, Aga DS (2005) Evaluating the biodegradability of sulfamethazine, sulfamethoxazole, sulfathiazole, and trimethoprim at different stages of sewage treatment. *Environ Toxicol Chem* 24:1361–1367
122. Batt AL, Kim S, Aga DS (2007) Comparison of the occurrence of antibiotics in four full-scale wastewater treatment plants with varying designs and operations. *Chemosphere* 68:428–435
123. Kobayashi Y, Yasojima M, Komori K, Suzuki Y, Tanaka H (2006) Removal characteristics of human antibiotics during wastewater treatment in Japan. *Water Pract Technol* 1:1–9
124. Carberry J, Englande A (1983) *Sludge characteristics and behavior*. Martinus Nijhoff, Boston, MA
125. Lindberg RH, Olofsson U, Rendahl P, Johansson MI, Tysklind M, Andersson BAV (2006) Behavior of fluoroquinolones and trimethoprim during mechanical, chemical, and active sludge treatment of sewage water and digestion of sludge. *Environ Sci Technol* 40: 1042–1048
126. Tolls J (2001) Sorption of veterinary pharmaceuticals in soils: a review. *Environ Sci Technol* 35:3397–3406
127. Suarez S, Carballa M, Omil F, Lema JM (2008) How are pharmaceutical and personal care products (PPCPs) removed from urban wastewaters? *Reviews in Environmental Science and Biotechnology* 7:125–138
128. Huggett DB, Khan IA, Foran CM, Schlenk D (2003) Determination of beta-adrenergic receptor blocking pharmaceuticals in united states wastewater effluent. *Environmental Pollution* 121:199–205

Emerging and Priority Pollutants in Rivers
Bringing Science into River Management Plans
Guasch, H.; Ginebreda, A.; Geislinger, A. (Eds.)
2012, XIV, 270 p., Hardcover
ISBN: 978-3-642-25721-6